Haven Capital Group, Inc. Iovance Biotherapeutics, Inc. Transaction History
Haven Capital Group, Inc.
- $113 Billion
- Q2 2025
A detailed history of Haven Capital Group, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Haven Capital Group, Inc. holds 106,512 shares of IOVA stock, worth $238,586. This represents 0.16% of its overall portfolio holdings.
Number of Shares
106,512
Previous 121,911
12.63%
Holding current value
$238,586
Previous $406 Million
54.93%
% of portfolio
0.16%
Previous 0.45%
Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
293Shares Held
233MCall Options Held
1.14MPut Options Held
1.15M-
Mhr Fund Management LLC New York, NY29MShares$64.9 Million8.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA25.1MShares$56.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$47.5 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR11.8MShares$26.5 Million0.94% of portfolio
-
State Street Corp Boston, MA9.89MShares$22.2 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $353M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...